Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

EyePoint Pharmaceuticals, Inc. - Common Stock (NQ:EYPT)

11.58 +0.07 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about EyePoint Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 Next >
News headline image
Bragar Eagel & Squire, P.C. Is Investigating Compass, EyePoint, F45, and PROG and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Meet The Company Bringing New Treatments For Serious Eye Issues To Market ↗
Sign up for this week’s All Access giveaway here! 
Via Benzinga
News headline image
EYEPOINT ALERT: Bragar Eagel & Squire, P.C. is Investigating EyePoint Pharmaceuticals, Inc. on Behalf of EyePoint Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
EyePoint Pharma Posts 12-Month Safety, Efficacy Data From Early-Stage Wet AMD Trial ↗
 
Via Benzinga
News headline image
Chardan Forecasts Over 160% Upside On This Eye Disease-Focused Stock ↗
 
Via Benzinga
News headline image
EyePoint, Expands Pact With Betta Pharma For EYP-1901 In China, Posts Deeper Q1 Loss ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
News headline image
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
News headline image
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
News headline image
The Law Offices of Frank R. Cruz Announces Investigation of EyePoint Pharmaceuticals, Inc. (EYPT) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in EyePoint Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: EyePoint Pharmaceuticals Q2 Earnings ↗
  EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:30 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Preview For EyePoint Pharmaceuticals ↗
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Recap of Monday's Biotech Catalysts - End of the Day Summary ↗
Abbvie (NYSE: ABBV) has submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for atogepant for the prophylaxis of migraine in adult patients who have at least... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
  
Via Benzinga
News headline image
EyePoint Announces Positive Safety and Efficacy Data From Initial-Stage Wet AMD Study ↗
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced 12-month data readout from the Phase 1 DAVIO clinical trial evaluating EYP-1901, targeting wet age-related macular degeneration (wet AMD) as a... 
Via Benzinga
News headline image
Why Bank Stocks Traded Sharply Higher; Here's 65 Biggest Movers From Friday ↗
Gainers United Maritime Corporation (NASDAQ: USEA) shares climbed 175.9% to close at $6.07 on Friday. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering... 
Via Benzinga
News headline image
7 Wildly Oversold Nasdaq Stocks to Buy Now ↗
For speculators that are seeking the next big upside opportunity, you may consider these oversold Nasdaq stocks to buy now. 
Via InvestorPlace
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 7, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Recap of Tuesday's Biotech Catalysts - End of the Day Summary ↗
Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid... 
Via Benzinga
News headline image
Recap: EyePoint Pharmaceuticals Q1 Earnings ↗
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
EyePoint Pharmaceuticals Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗
EyePoint Pharmaceuticals (NASDAQ:EYPT) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
EyePoint Pharma Secures $45M Credit Facilities For Debt Refinancing ↗
EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has secured senior secured credit facilities of $45 million from Silicon Valley Bank to replace its existing... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Gainers Tonix Pharmaceuticals (NASDAQ:TNXP) stock rose 49.1% to $0.28 during Thursday's regular session. As of 12:31 EST, Tonix Pharmaceuticals's stock is trading... 
Via Benzinga
News headline image
Recap: EyePoint Pharmaceuticals Q4 Earnings ↗
EyePoint Pharmaceuticals (NASDAQ:EYPT) reported its Q4 earnings results on Thursday, March 3, 2022 at 07:00 AM. Here's what investors need to know about the... 
Via Benzinga
News headline image
Earnings Preview: EyePoint Pharmaceuticals ↗
EyePoint Pharmaceuticals (NASDAQ:EYPT) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement.... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
News headline image
Earnings Scheduled For March 3, 2022 ↗
Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.